Indian adversarial — medicines, IP, farmers

The critical Indian-left view: warns of 'TRIPS-plus' provisions, especially up-to-12-year data exclusivity that could block generics and hollow out Section 3(d) of India's Patent Act, threatening the 'pharmacy of the world' even as Delhi shielded dairy and grains.

“Data exclusivity blocks generic companies from using existing clinical data to register medicines for up to 12 years, regardless of whether a patent exists.”